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Introduction {#jdi13207-sec-0005}
============

Hyperuricemia is closely associated with obesity and metabolic disturbances, such as insulin resistance, dyslipidemia, hypertension and cardiovascular diseases[1](#jdi13207-bib-0001){ref-type="ref"}, [2](#jdi13207-bib-0002){ref-type="ref"}, [3](#jdi13207-bib-0003){ref-type="ref"}. In the purine metabolism pathway, uric acid is synthesized by oxidation of hypoxanthine and xanthine using a catalyzing enzyme, xanthine oxidoreductase (XOR)[4](#jdi13207-bib-0004){ref-type="ref"}. XOR is inducted as xanthine dehydrogenase, which catalyzes the reduction of oxidized nicotinamide adenine dinucleotide (NAD^+^) to reduced nicotinamide adenine dinucleotide (NADH), and is post‐translationally converted to xanthine oxidase, which produces hydrogen peroxide and superoxide by using oxygen[4](#jdi13207-bib-0004){ref-type="ref"}. Therefore, XOR can be an important source of reactive oxygen species, and it contributes to the development of oxidative stress‐associated tissue disturbances[5](#jdi13207-bib-0005){ref-type="ref"}.

Plasma hypoxanthine is an extracellular molecule that reflects intracellular energy metabolism[6](#jdi13207-bib-0006){ref-type="ref"}, leading to a marker of hypoxia in tissue[7](#jdi13207-bib-0007){ref-type="ref"}, [8](#jdi13207-bib-0008){ref-type="ref"} and free radical formation after reperfusion[9](#jdi13207-bib-0009){ref-type="ref"}. Therefore, plasma hypoxanthine is used as a tool for the diagnosis of hypoxia‐related diseases, including cardiovascular disease, respiratory disease and hemolytic disorders[10](#jdi13207-bib-0010){ref-type="ref"}. Hypoxanthine is released from cells under a condition of hypoxia into the blood circulation[11](#jdi13207-bib-0011){ref-type="ref"}, [12](#jdi13207-bib-0012){ref-type="ref"}, [13](#jdi13207-bib-0013){ref-type="ref"}, and is finally incorporated into the liver and metabolized to uric acid[14](#jdi13207-bib-0014){ref-type="ref"}. As production of hypoxanthine in several tissues, including fat tissue, contributes to the production of uric acid through XOR, it has been suggested that the disturbance of purine catabolism in several tissues other than the liver as a main organ is, at least in part, related to free radical formation as well as hyperuricemia[15](#jdi13207-bib-0015){ref-type="ref"}.

As activity of plasma XOR is much lower in humans than in animals[16](#jdi13207-bib-0016){ref-type="ref"}, it has been difficult to accurately measure the activity in humans. An accurate and sensitive assay for activity of plasma XOR in humans has been newly developed using liquid chromatography and triple quadrupole mass spectrometry to measure \[^13^C~2~, ^15^N~2~\]‐uric acid using \[^13^C~2~, ^15^N~2~\]‐xanthine as a substrate[17](#jdi13207-bib-0017){ref-type="ref"}. Using this assay, we and others have shown that activity of plasma XOR is a novel metabolic biomarker associated with obesity, insulin resistance, hyperuricemia, liver dysfunction and adipokines[18](#jdi13207-bib-0018){ref-type="ref"}, [19](#jdi13207-bib-0019){ref-type="ref"}, [20](#jdi13207-bib-0020){ref-type="ref"}, [21](#jdi13207-bib-0021){ref-type="ref"}. Furthermore, we showed unexpected high activity of plasma XOR in some hyperuricemic patients by using an XOR inhibitor[19](#jdi13207-bib-0019){ref-type="ref"} and in some female relatively hypouricemic patients [22](#jdi13207-bib-0022){ref-type="ref"}.

XOR is strongly expressed in adipose tissue of murine models, and formation of uric acid can be increased in obesity‐related insulin resistance[23](#jdi13207-bib-0023){ref-type="ref"}. In our previous study carried out with 627 participants, activity of plasma XOR was found to be independently associated with body mass index (BMI) and uric acid in a general population[19](#jdi13207-bib-0019){ref-type="ref"}. However, it has recently been reported that activity of XOR in human fat tissue is much lower than that in mouse fat tissue and that in the mouse liver[15](#jdi13207-bib-0015){ref-type="ref"}. Furthermore, hypoxanthine is secreted from human fat tissue, particularly under a hypoxia condition[15](#jdi13207-bib-0015){ref-type="ref"}. In addition, a previous study showed that plasma hypoxanthine levels were significantly lower in lean individuals (*n* = 16) than in obese individuals (*n* = 7)[13](#jdi13207-bib-0013){ref-type="ref"}. These findings suggest that human fat tissue might be a source of hypoxanthine as a substrate of XOR, but not a source of XOR itself, in the purine catabolism pathway. In the present study, we investigated the significance and association of hypoxanthine, xanthine and plasma XOR activity in a general population.

Methods {#jdi13207-sec-0006}
=======

Study participants {#jdi13207-sec-0007}
------------------

In our population‐based cohort, the Tanno‐Sobetsu Study, 605 Japanese individuals (men/women: 280/325) of Sobetsu Town underwent annual examinations in 2017. Among them, 121 individuals (men/women: 56/65) were excluded, as the time until blood processing of centrifugal plasma separation was \>3 h, which might affect concentrations of hypoxanthine and xanthine by leakage from erythrocytes[24](#jdi13207-bib-0024){ref-type="ref"}, [25](#jdi13207-bib-0025){ref-type="ref"}, [26](#jdi13207-bib-0026){ref-type="ref"}. A total of 484 individuals (men/women: 224/260) were enrolled in the present study. This study was approved by the ethical committee of Sapporo Medical University, and was carried out under the principles of the Declaration of Helsinki. Written informed consent was received from all of the participants.

Measurements {#jdi13207-sec-0008}
------------

Medical health checkups, including measurements of biochemical parameters and blood pressure, and calculation of BMI, estimated glomerular filtration rate (eGFR) and homeostasis model assessment of insulin resistance (HOMA‐IR) were carried out as previously described[19](#jdi13207-bib-0019){ref-type="ref"}. Hemoglobin A1c (HbA1c) level was presented as the National Glycohemoglobin Standardization Program equivalent value.

Hypertension was diagnosed as the use of drugs for hypertension, systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. Diabetes mellitus was diagnosed as the use of drugs for diabetes mellitus or a combination of fasting glucose ≥126 mg/dL and HbA1c ≥6.5%. Dyslipidemia was diagnosed as the use of drugs for dyslipidemia, low‐density lipoprotein cholesterol ≥140 mg/dL, triglycerides ≥150 mg/dL or high‐density lipoprotein (HDL) cholesterol \<40 mg/dL. Hyperuricemia was diagnosed as the use of drugs for hyperuricemia or uric acid \>7 mg/dL.

Concentrations of hypoxanthine and xanthine {#jdi13207-sec-0009}
-------------------------------------------

Blood samples were obtained using a collection tube coated with ethylenediaminetetraacetic acid‐2K, and they were kept at 4°C until centrifugation. For plasma separation, the samples were centrifuged at 2,000 *g* for 10 min at 4°C. Plasma concentrations of xanthine and hypoxanthine were determined as previously reported[26](#jdi13207-bib-0026){ref-type="ref"}. In brief, plasma samples were added to methanol containing \[^13^C~2~, ^15^N~2~\] xanthine and \[^13^C~3~, ^15^N\] hypoxanthine as internal controls, and were centrifuged at 3,000 *g* for 15 min at 4°C. The supernatant (40 μL) was diluted with 160 μL distilled water, and concentrations of xanthine and hypoxanthine were measured using liquid chromatography and triple quadrupole mass spectrometry (Nexera SCIEX QTRAP 4500; SHIMADZU, Kyoto, Japan).

Measurement of plasma XOR activity {#jdi13207-sec-0010}
----------------------------------

Activity of XOR in plasma was determined by liquid chromatography and triple quadrupole mass spectrometry to detect \[^13^C~2~, ^15^N~2~\]‐uric acid using \[^13^C~2~, ^15^N~2~\]‐xanthine as a substrate as previously reported[17](#jdi13207-bib-0017){ref-type="ref"}, [19](#jdi13207-bib-0019){ref-type="ref"}. The lower detection limit was 6.67 pmol/h/mL plasma, and coefficients of variation in intra‐assay and interassay were 6.5 and 9.1%, respectively[17](#jdi13207-bib-0017){ref-type="ref"}.

Statistical analysis {#jdi13207-sec-0011}
--------------------

Numeric values are shown as the mean ± standard deviation for normal distributions or medians (interquartile ranges) for skewed variables. The distribution normality for each parameter was analyzed using the Shapiro--Wilk *W*‐test. Skewed parameters were logarithmically transformed for regression analyses. Intergroup differences in percentages of demographic values were analyzed by the χ^2^‐test. Comparison between two groups was analyzed using Student's *t*‐test for parametric parameters, and the Mann--Whitney *U*‐test for non‐parametric parameters. One‐way analysis of variance and the Tukey--Kramer post‐hoc test for parametric parameters, and the Kruskal--Wallis test and the Steel--Dwass post‐hoc test for non‐parametric parameters were carried out for testing significant differences in variables between multiple groups. The correlation between two values was carried out using Pearson's correlation coefficient. Stepwise and subsequent multivariate regression analyses were carried out to show independent parameters of hypoxanthine, xanthine, plasma XOR activity and uric acid using age, sex, use of antihyperuricemic drugs and variables with a significant correlation as independent predictors after consideration of multicollinearity based on the Akaike information criterion, showing the percentage of variance in the object variables that the chosen independent values explained (*R* ^2^), unstandardized regression coefficient and standard error of regression coefficient, the *t*‐ratio calculated as the ratio of regression coefficient and standard error, and the standardized regression coefficient (β). A *P* \< 0.05 was considered to be statistically significant. All statistical analyses were determined by using JMP for Macintosh (SAS Institute, Cary, NC, USA).

Results {#jdi13207-sec-0012}
=======

Basal characteristics of the participants {#jdi13207-sec-0013}
-----------------------------------------

The characteristics of the 484 recruited participants (men/women: 224/260, mean age 65 ± 15 years) are shown in Table [1](#jdi13207-tbl-0001){ref-type="table"}. Hypertension, dyslipidemia, diabetes mellitus and hyperuricemia were found in 276 (57%), 265 (54.8%), 59 (12.2%) and 59 (12.2%) participants, respectively. Male participants had significantly larger waist circumference and BMI; significantly higher frequencies of hyperuricemia, and drinking and smoking habits; higher levels of aspartate transaminase (AST), alanine aminotransferase (ALT), γ‐glutamyl transpeptidase (γGTP), blood urea nitrogen (BUN), creatinine, uric acid, triglycerides, fasting glucose, hypoxanthine, xanthine and activity of plasma XOR; and lower levels of total cholesterol, low‐density lipoprotein cholesterol and HDL cholesterol than did female participants. There was no significant sex difference in age, blood pressure, eGFR, HbA1c, insulin or HOMA‐IR.

###### 

Participant characteristics

                                    Total (*n* = 484)   Men (*n* = 224)     Women (*n* = 260)   *P*
  --------------------------------- ------------------- ------------------- ------------------- ---------
  Age (years)                       65 ± 15             65 ± 15             65 ± 15             0.910
  Body mass index (kg/m^2^)         23.4 ± 3.9          24.0 ± 3.7          22.9 ± 4.1          0.001
  Waist circumference (cm)          85.1 ± 11.1         86.8 ± 10.6         83.6 ± 11.2         0.002
  Systolic blood pressure (mmHg)    137 ± 21            137 ± 18            138 ± 23            0.536
  Diastolic blood pressure (mmHg)   77 ± 11             77 ± 11             76 ± 11             0.144
  Smoking habit                     75 (15.5)           50 (22.3)           25 (9.6)            \<0.001
  Alcohol drinking habit            200 (41.3)          129 (57.6)          71 (27.3)           \<0.001
  Disease                                                                                       
  Hypertension                      276 (57.0)          129 (57.6)          147 (56.5)          0.816
  Diabetes mellitus                 59 (12.2)           34 (15.2)           25 (9.6)            0.062
  Dyslipidemia                      265 (54.8)          120 (53.6)          145 (55.8)          0.628
  Hyperuricemia                     59 (12.2)           51 (22.8)           8 (3.1)             \<0.001
  Medications                                                                                   
  Antihypertensive drugs            171 (35.3)          80 (35.7)           91 (35.0)           0.870
  Antidiabetic drugs                47 (9.7)            27 (12.1)           20 (7.7)            0.106
  Antidyslipidemic drugs            103 (21.3)          39 (17.4)           64 (24.6)           0.054
  Antihyperuricemic drugs           14 (2.9)            12 (5.4)            2 (0.8)             0.003
  Biochemical data                                                                              
  AST (IU/L)                        24 (21--28)         25 (21--30)         23 (20--26)         \<0.001
  ALT (IU/L)                        19 (15--25)         23 (17--30)         17 (14--22)         \<0.001
  γGTP (IU/L)                       22 (16--34)         28 (20--42)         18 (15--26)         \<0.001
  Blood urea nitrogen (mg/dL)       16 ± 5              17 ± 5              15 ± 4              \<0.001
  Creatinine (mg/dL)                0.8 (0.7--0.9)      0.9 (0.8--1.0)      0.7 (0.6--0.8)      \<0.001
  eGFR (mL/min/1.73 m^2^)           67 ± 14             69 ± 16             66 ± 13             0.052
  Uric acid (mg/dL)                 5.3 ± 1.3           6.0 ± 1.2           4.8 ± 1.1           \<0.001
  Total cholesterol (mg/dL)         207 ± 36            199 ± 34            214 ± 36            \<0.001
  LDL cholesterol (mg/dL)           119 ± 29            115 ± 29            123 ± 29            0.002
  HDL cholesterol (mg/dL)           65 ± 19             59 ± 16             71 ± 20             \<0.001
  Triglycerides (mg/dL)             91 (67--122)        95 (68--134)        88 (64--109)        0.006
  Fasting glucose (mg/dL)           95 (88--104)        98 (90--108)        93 (87--101)        \<0.001
  Insulin (µU/mL)                   4.9 (3.3--7.0)      4.9 (3.3--7.5)      4.9 (3.4--6.9)      0.707
  HOMA‐IR                           0.39 (0.29--0.51)   0.40 (0.30--0.52)   0.38 (0.28--0.48)   0.110
  HbA1c (%)                         5.6 (5.3--5.9)      5.6 (5.4--6.0)      5.6 (5.3--5.8)      0.082
  Hypoxanthine (µmol/L)             3.1 ± 1.6           3.3 ± 1.7           2.9 ± 1.4           0.003
  Xanthine (µmol/L)                 0.9 (0.7--1.1)      0.9 (0.7--1.3)      0.8 (0.7--1.0)      \<0.001
  XOR activity (pmol/h/mL plasma)   38.0 (25.2--67.8)   46.4 (29.6--88.6)   32.4 (22.6--54.8)   \<0.001

Variables are expressed as number (%), mean ± standard deviation or median (interquartile range).

γGTP, γ‐glutamyl transpeptidase; ALT, alanine transaminase; AST, aspartate transaminase; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HOMA‐IR, homeostasis model assessment of insulin resistance; LDL, low‐density lipoprotein; XOR, xanthine oxidoreductase.
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Participants treated with an XOR inhibitor {#jdi13207-sec-0014}
------------------------------------------

Of 59 participants (men/women: 51/8) with hyperuricemia, 14 (men/women: 12/2) participants were being treated with antihyperuricemic drugs, including XOR inhibitors (men/women: 11/0) and benzbromarone (men/women: 1/2). Characteristics of the 11 men being treated with an XOR inhibitor (febuxostat/allopurinol: 3/8) are shown in Table [S1](#jdi13207-sup-0001){ref-type="supplementary-material"}. Among them, plasma XOR activities in three patients (participants \#9--11) were more than the upper quartile of the activity (88.6 pmol/h/mL plasma) in male participants, and the three patients had liver dysfunction or a smoking habit, and were being treated for diabetes mellitus and/or dyslipidemia.

When male participants were divided by the absence and presence of hyperuricemia treated with or not treated with an XOR inhibitor, the level of uric acid in hyperuricemic patients treated with an XOR inhibitor (*n* = 11) was significantly lower than that in hyperuricemic patients without treatment (*n* = 40), but was still significantly higher than that in participants without hyperuricemia (*n* = 173; Figure [1](#jdi13207-fig-0001){ref-type="fig"}a). There was no significant intergroup difference in levels of plasma XOR activity (Figure [1](#jdi13207-fig-0001){ref-type="fig"}b) or hypoxanthine (Figure [1](#jdi13207-fig-0001){ref-type="fig"}c). Male participants with hyperuricemia who were being treated with an XOR inhibitor had a significantly higher level of xanthine than did that in participants without treatment and that in participants without hyperuricemia (Figure [1](#jdi13207-fig-0001){ref-type="fig"}d).

![Comparisons of purine metabolism‐related parameters in male subjects treated with and without an xanthine oxidoreductase inhibitor (XORi). (a--d) Comparisons of (a) uric acid, (b) plasma xanthine oxidoreductase (XOR) activity, (c) hypoxanthine and (d) xanthine in male participants without hyperuricemia (Non‐HU, *n* = 173) and male patients with hyperuricemia in the absence (HU, *n* = 40) and the presence (HU‐XORi, *n* = 11) of treatment with an XOR inhibitor. \**P* \< 0.05 versus non‐HU, ^†^ *P* \< 0.05 versus HU.](JDI-11-878-g001){#jdi13207-fig-0001}

In women, uric acid level in participants with hyperuricemia (*n* = 8) was significantly higher than that in participants without hyperuricemia (*n* = 252; Figure [S1](#jdi13207-sup-0001){ref-type="supplementary-material"}a). There was no significant difference between participants with and those without hyperuricemia in levels of plasma XOR activity (Figure [S1](#jdi13207-sup-0001){ref-type="supplementary-material"}b), hypoxanthine (Figure [S1](#jdi13207-sup-0001){ref-type="supplementary-material"}c) or xanthine (Figure [S1](#jdi13207-sup-0001){ref-type="supplementary-material"}d).

Comparisons of levels of hypoxanthine, xanthine and plasma XOR activity by habits of smoking and alcohol drinking {#jdi13207-sec-0015}
-----------------------------------------------------------------------------------------------------------------

The concentration of hypoxanthine (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}a), but not the concentration of xanthine (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}b) or plasma XOR activity (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}c), in smokers was significantly higher than that in non‐smokers. Uric acid level was significantly higher in smokers than in non‐smokers (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}d). No significant difference was found between levels of hypoxanthine (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}e), xanthine (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}f) or plasma XOR activity (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}g) in participants with and those without an alcohol drinking habit. Uric acid level was significantly higher in participants with an alcohol drinking habit than in those without the habit (Figure [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}h).

Associations of hypoxanthine level with clinical variables {#jdi13207-sec-0016}
----------------------------------------------------------

As shown in Table [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}, the concentration of hypoxanthine was positively correlated with BMI (Figure [2](#jdi13207-fig-0002){ref-type="fig"}a), waist circumference and levels of γGTP, ALT, eGFR, triglycerides, uric acid, HOMA‐IR and xanthine (Figure [2](#jdi13207-fig-0002){ref-type="fig"}b), and was negatively correlated with age and levels of HDL cholesterol and BUN. Similar correlations of hypoxanthine with BMI, waist circumference and xanthine were found when sex was separately tested (Table [S2](#jdi13207-sup-0001){ref-type="supplementary-material"}).

![Correlations of hypoxanthine, xanthine and plasma xanthine oxidoreductase (XOR) activity with metabolic parameters. (a) Body mass index and (b) logarithmically transformed (log) xanthine were plotted against the plasma level of hypoxanthine in each participant (*n* = 484). (c) Log alanine aminotransferase (ALT) and (d) log plasma XOR activity were plotted against log xanthine in each participant. (e) Log ALT and (f) log triglycerides were plotted against log XOR in each participant. Open circles and broken regression line, men (*n* = 224); closed circles and solid regression line, women (*n* = 260). M/F, male/female.](JDI-11-878-g002){#jdi13207-fig-0002}

Stepwise multivariate regression analyses for hypoxanthine using age, sex, use of antihyperuricemic drugs, smoking habit and the correlated parameters as possible predictors showed that BMI (β = 0.106, *P* = 0.008), smoking habit (β = 0.118, *P* = 0.005) and xanthine (β = 0.468, *P* \< 0.001) were independently associated with hypoxanthine after adjustment of age, sex and use of antihyperuricemic drugs (*R* ^2^ = 0.307; Table [2](#jdi13207-tbl-0002){ref-type="table"}).

###### 

Multivariate regression analyses for hypoxanthine, xanthine, xanthine oxidoreductase activity and uric acid

                                   Regression coefficient   SE      Standardized regression coefficient (β)   *t*     *P*
  -------------------------------- ------------------------ ------- ----------------------------------------- ------- ---------
  Hypoxanthine                                                                                                        
  Age                              −0.018                   0.004   −0.175                                    −4.27   \<0.001
  Sex (male)                       0.001                    0.063   0.001                                     0.02    0.988
  Use of antihyperuricemic drugs   −0.098                   0.185   −0.021                                    −0.53   0.595
  Body mass index                  0.042                    0.016   0.106                                     2.66    0.008
  Smoking habit                    0.250                    0.088   0.118                                     2.83    0.005
  log Xanthine                     1.501                    0.134   0.468                                     11.22   \<0.001
  *R* ^2^ = 0.307                                                                                                      
  log Xanthine                                                                                                        
  Age                              0.003                    0.001   0.105                                     2.90    0.004
  Sex (Male)                       0.017                    0.018   0.034                                     0.92    0.357
  Use of antihyperuricemic drugs   0.275                    0.051   0.192                                     5.37    \<0.001
  log ALT                          0.173                    0.052   0.163                                     3.30    0.001
  Hypoxanthine                     0.141                    0.011   0.456                                     12.59   \<0.001
  log XOR                          0.130                    0.029   0.215                                     4.51    \<0.001
  *R* ^2^ = 0.416                                                                                                      
  log XOR                                                                                                             
  Age                              0.003                    0.002   0.052                                     1.58    0.115
  Sex (Male)                       −0.003                   0.028   −0.004                                    −0.11   0.912
  Use of antihyperuricemic drugs   −0.219                   0.081   −0.092                                    −2.69   0.007
  log ALT                          1.071                    0.066   0.607                                     16.19   \<0.001
  log Triglycerides                0.179                    0.052   0.119                                     3.41    0.001
  log Xanthine                     0.198                    0.061   0.119                                     3.22    0.001
  *R* ^2^ = 0.489                                                                                                      
  Uric acid                                                                                                           
  Age                              −0.021                   0.004   −0.243                                    −5.42   \<0.001
  Sex (Male)                       0.505                    0.050   0.396                                     10.09   \<0.001
  Use of antihyperuricemic drugs   −0.025                   0.143   −0.007                                    −0.17   0.862
  Body mass index                  0.030                    0.013   0.093                                     2.38    0.018
  log ALT                          0.498                    0.118   0.176                                     4.21    \<0.001
  eGFR                             −0.031                   0.004   −0.352                                    −7.66   \<0.001
  log Triglycerides                0.277                    0.094   0.115                                     2.94    0.003
  *R* ^2^ = 0.358                                                                                                      

ALT, alanine transaminase; eGFR, estimated glomerular filtration rate; SE, standard error; XOR, xanthine oxidoreductase.
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Associations of xanthine level with clinical variables {#jdi13207-sec-0017}
------------------------------------------------------

As shown in Table [S3](#jdi13207-sup-0001){ref-type="supplementary-material"}, the concentration of xanthine was positively correlated with BMI, waist circumference, diastolic blood pressure, and levels of ALT (Figure [2](#jdi13207-fig-0002){ref-type="fig"}c), AST, γGTP, creatinine, triglycerides, uric acid, fating glucose, HbA1c and hypoxanthine, and activity of plasma XOR (Figure [2](#jdi13207-fig-0002){ref-type="fig"}d), and was negatively correlated with level of HDL cholesterol. Similar correlations between the parameters, except diastolic blood pressure, creatinine, HbA1c and HDL cholesterol, were found when sex was separately tested (Table [S3](#jdi13207-sup-0001){ref-type="supplementary-material"}).

Stepwise multivariate regression analyses for xanthine using age, sex, use of antihyperuricemic drugs and the correlated parameters as possible determinants showed that use of antihyperuricemic drugs (β = 0.192, *P* \< 0.001), ALT (β = 0.163, *P* = 0.001), hypoxanthine (β = 0.456, *P* \< 0.001) and plasma XOR activity (β = 0.215, *P* \< 0.001) were independently associated with xanthine after adjustment of age and sex (*R* ^2^ = 0.416; Table [2](#jdi13207-tbl-0002){ref-type="table"}).

Associations of plasma XOR activity with clinical variables {#jdi13207-sec-0018}
-----------------------------------------------------------

As shown in Table [S4](#jdi13207-sup-0001){ref-type="supplementary-material"}, plasma XOR activity was positively correlated with waist circumference, BMI, systolic and diastolic blood pressures, and levels of AST, ALT (Figure [2](#jdi13207-fig-0002){ref-type="fig"}e), γGTP, uric acid, eGFR, triglycerides (Figure [2](#jdi13207-fig-0002){ref-type="fig"}f), fating glucose, insulin, HOMA‐IR, HbA1c and xanthine, and was negatively correlated with HDL cholesterol level. Similar correlations between the variables, except systolic and diastolic blood pressures, eGFR, HDL cholesterol, fasting glucose, insulin, HOMA‐IR and HbA1c, were found when sex was separately tested (Table [S4](#jdi13207-sup-0001){ref-type="supplementary-material"}).

Stepwise multivariate regression analyses for activity of XOR in plasma using age, sex, use of antihyperuricemic drugs and the correlated parameters as possible determinants showed that use of antihyperuricemic drugs (β = −0.092, *P* = 0.007), ALT (β = 0.607, *P* \< 0.001), triglycerides (β = 0.119, *P* = 0.001) and xanthine (β = 0.119, *P* = 0.001) were independently associated with plasma XOR activity after adjustment of age and sex (*R* ^2^ = 0.489; Table [2](#jdi13207-tbl-0002){ref-type="table"}).

Associations of uric acid with clinical variables {#jdi13207-sec-0019}
-------------------------------------------------

As shown in Table [S5](#jdi13207-sup-0001){ref-type="supplementary-material"}, the concentration of uric acid was positively correlated with BMI, waist circumference, diastolic blood pressure and levels of AST, ALT, γGTP, BUN, creatinine, triglycerides, hypoxanthine, xanthine and activity of plasma XOR, and was negatively correlated with levels of eGFR and HDL cholesterol. Similar correlations between the variables, except diastolic blood pressures, BUN, eGFR, HDL cholesterol and hypoxanthine, were found when sex was separately tested (Table [S5](#jdi13207-sup-0001){ref-type="supplementary-material"}).

Stepwise multivariate regression analyses for uric acid using age, sex, use of antihyperuricemic drugs, habits of smoking and alcohol drinking, and the correlated parameters as possible predictors showed that BMI (β = 0.093, *P* = 0.018), ALT (β = 0.176, *P* \< 0.001), eGFR (β = −0.352, *P* \< 0.001) and triglycerides (β = 0.115, *P* = 0.003) were independently associated with uric acid after adjustment of age, sex and use of antihyperuricemic drugs (*R* ^2^ = 0.358; Table [2](#jdi13207-tbl-0002){ref-type="table"}).

Discussion {#jdi13207-sec-0020}
==========

The present study showed differential regulation of circulating hypoxanthine and xanthine in a general population. The concentration of hypoxanthine, but not that of xanthine, was independently associated with BMI (β = 0.106, *P* = 0.008) and smoking habit (β = 0.118, *P* = 0.005) after adjustment of age, sex and use of antihyperuricemic drugs (Table [2](#jdi13207-tbl-0002){ref-type="table"}). In contrast, the level of xanthine was independently associated with ALT as a liver enzyme, hypoxanthine as an upstream metabolite of xanthine, and activity of plasma XOR, an enzyme of purine metabolism using xanthine as a substrate, after adjustment of age, sex and the use of antihyperuricemic drugs (Table [2](#jdi13207-tbl-0002){ref-type="table"}). BMI was not selected as an independent determinant of xanthine or activity of plasma XOR in the present study. Furthermore, men who were being treated with an XOR inhibitor had a significantly higher level of xanthine, but not hypoxanthine, than did that in participants without treatment (Figure [1](#jdi13207-fig-0001){ref-type="fig"}c, d).

Regarding the association of hypoxanthine with BMI, a similar study using a small number of participants showed that the plasma level of hypoxanthine was significantly higher in participants with obesity (*n* = 7) than in lean participants (*n* = 16)[13](#jdi13207-bib-0013){ref-type="ref"}. It has been reported that the tissue content of hypoxanthine in human adipose tissue is higher than the contents of xanthine and uric acid, and that human fat tissue mainly produces hypoxanthine among purine catabolism‐related metabolites[15](#jdi13207-bib-0015){ref-type="ref"}. In a condition of hypoxia, adenosine triphosphate is degraded to hypoxanthine through adenosine diphosphate, adenosine monophosphate, adenosine and inosine[25](#jdi13207-bib-0025){ref-type="ref"}, and hypoxanthine, a nucleobase, is secreted from cells through several transporters, including equilibrative nucleobase transporter 1 and equilibrative nucleoside transporters[26](#jdi13207-bib-0026){ref-type="ref"}, [27](#jdi13207-bib-0027){ref-type="ref"}, [28](#jdi13207-bib-0028){ref-type="ref"}, [29](#jdi13207-bib-0029){ref-type="ref"}. It has also been shown that hypoxia increases the production of hypoxanthine in human adipocytes[15](#jdi13207-bib-0015){ref-type="ref"}. In an obese condition, the amount of adipose tissue, especially in visceral fat, generally increases with an increase in adipocyte size rather than an increase in the number of adipocytes[30](#jdi13207-bib-0030){ref-type="ref"}, [31](#jdi13207-bib-0031){ref-type="ref"}, and oxygen partial pressure in fat tissues is low in obesity in both mice and humans[32](#jdi13207-bib-0032){ref-type="ref"}, [33](#jdi13207-bib-0033){ref-type="ref"}, [34](#jdi13207-bib-0034){ref-type="ref"}, [35](#jdi13207-bib-0035){ref-type="ref"}, [36](#jdi13207-bib-0036){ref-type="ref"}, [37](#jdi13207-bib-0037){ref-type="ref"}. Therefore, hypertrophic visceral adipocytes might be more affected by local hypoxia, leading to hypoxanthine overproduction. An increase in whole body fat mass and local hypoxia in obese fat tissue might boost the production of hypoxanthine from fat tissue.

In the present study, hypoxanthine concentration was found to be independently associated with current habitual smoking, possibly caused by local hypoxia in several lung cells. It has also been reported that nicotine degrades a purine salvage enzyme, hypoxanthine‐guanine phosphoribosyltransferase (HGPRT)[38](#jdi13207-bib-0038){ref-type="ref"}, and that smoking lowers the activity of HGPRT[39](#jdi13207-bib-0039){ref-type="ref"}, suggesting an increase in plasma hypoxanthine levels by inhibition of salvage pathway. In contrast, unlike in a previous study[19](#jdi13207-bib-0019){ref-type="ref"}, there was no significant difference in plasma activities of XOR between participants with and those without a smoking habit in the present study. The discrepant results might be caused by the number of cigarettes smoked and the time of cessation from the cigarette smoked in the recruited participants. Hypoxia might affect hypoxanthine more than XOR activity. The induction of hypoxanthine as a substrate of XOR in the purine metabolism pathway might contribute to the activation of plasma XOR activity and the increase in oxidative stress, eventually leading to uric acid production as an anti‐oxidant molecule.

Men with hyperuricemia who were being treated with an XOR inhibitor did not have a significantly lower plasma XOR activity than that in participants without treatment (Figure [1](#jdi13207-fig-0001){ref-type="fig"}b). The main reason was that some of the patients (participants \#9--11) had high plasma XOR activities, despite treatment with an XOR inhibitor (Table [S1](#jdi13207-sup-0001){ref-type="supplementary-material"}). Those participants, who had liver dysfunction or a smoking habit and were being treated for diabetes mellitus and/or dyslipidemia, might be resistant to an XOR inhibitor, as previously reported[19](#jdi13207-bib-0019){ref-type="ref"}.

Both xanthine and hypoxanthine are oxypurines and precursors of uric acid, which are oxidized by XOR, in purine catabolism[4](#jdi13207-bib-0004){ref-type="ref"}. Therefore, XOR inhibitors are thought to increase the upstream metabolites. A previous study showed enhanced purine salvage during administration of allopurinol, an XOR inhibitor, in humans[40](#jdi13207-bib-0040){ref-type="ref"}. The present study showed that men who were being treated with an XOR inhibitor had a significantly higher level of xanthine, but not hypoxanthine, than that in men without treatment. Hypoxanthine is simultaneously metabolized to a purine nucleotide, inosine monophosphate, by HGPRT in the salvage pathway of purine metabolism, which recycles the basic materials for reconstitution of DNA, RNA and purine nucleotides, including adenosine triphosphate, without adenosine triphosphate expenditure, and cooperates with the de novo pathway of purine metabolism[4](#jdi13207-bib-0004){ref-type="ref"}, [6](#jdi13207-bib-0006){ref-type="ref"}, [41](#jdi13207-bib-0041){ref-type="ref"}. Normally, approximately 90% of hypoxanthine is reutilized and converted to inosine monophosphate through the salvage pathway[25](#jdi13207-bib-0025){ref-type="ref"}. In hereditary xanthinuria caused by XOR deficiency, hypoxanthinuria is not observed because of the salvage pathway of purine metabolism by HGPRT[42](#jdi13207-bib-0042){ref-type="ref"}, [43](#jdi13207-bib-0043){ref-type="ref"}. The lack of an increase in hypoxanthine by XOR inhibitors in the present study was probably due to activation of the salvage pathway.

Taken together, the results show the following important effects of XOR inhibitors: (i) a decrease in uric acid for preventing gout; (ii) reduction of XOR activity for subsequent inhibition of reactive oxygen species, including hydrogen peroxide and superoxide; and (iii) energy supply from hypoxanthine through the salvage pathway. Interventional studies using a large number of patients treated with and not treated with an XOR inhibitor are required to clarify the significance of measurements of hypoxanthine, xanthine and plasma XOR activity.

The present study had some limitations. First, whether the results can be generalized to other ethnicities is unclear, as the recruited participants were only Japanese people. Second, the number of cigarettes smoked, passive smoking and regular exercise, which might affect oxypurines and activity of XOR[13](#jdi13207-bib-0013){ref-type="ref"}, [19](#jdi13207-bib-0019){ref-type="ref"}, were not investigated in the present study. Third, the origins of hypoxanthine, xanthine and uric acid would be from not only tissues including adipose tissue and the liver, but also reaction in plasma. Appropriate assessments of reactions in plasma of oxypurines need to be considered in future analysis. Finally, the time until plasma separation, which might affect plasma XOR activity and concentrations of xanthine and hypoxanthine by leakage from erythrocytes[24](#jdi13207-bib-0024){ref-type="ref"}, [25](#jdi13207-bib-0025){ref-type="ref"}, varied, as blood samples were obtained in the rural town of Sobetsu, and were transported to and centrifuged in a central laboratory. A previous study using blood samples in a tube coated with ethylenediaminetetraacetic acid‐2K showed that 3 h, but not 6 h, until plasma separation did not cause a significant increase in the level of hypoxanthine or xanthine[26](#jdi13207-bib-0026){ref-type="ref"}. Therefore, participants for whom the time until blood processing was \>3 h were excluded from the present study. It has recently been proposed that using a commercially available tube (PAXgene Blood DNA tube; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) for blood collection enables accurate measurements of hypoxanthine and xanthine regardless of the time until plasma separation[26](#jdi13207-bib-0026){ref-type="ref"}.

In conclusion, the concentration of hypoxanthine is independently associated with BMI and smoking habit, whereas the level of xanthine is associated with parameters of mainly purine metabolism in the liver, including ALT, hypoxanthine and plasma XOR activity, indicating differential regulation of hypoxanthine and xanthine in a general population. In obesity, human adipose tissue would be a source of hypoxanthine as a substrate of XOR in the purine metabolism pathway. The reduction of adiposity and cessation of smoking might be novel therapeutic strategies for adipose‐derived hypoxanthine‐mediated metabolic disorders.
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**Figure S1** \| Comparisons of purine metabolism‐related parameters in female participants with and without hyperuricemia.

**Figure S2** \| Comparisons of hypoxanthine, xanthine, xanthine oxidoreductase (XOR) activity and uric acid with habits of smoking and alcohol drinking.

**Table S1** \| Characteristics of 11 participants treated with an xanthine oxidoreductase inhibitor.

**Table S2** \| Correlation analysis for hypoxanthine.

**Table S3** \| Correlation analysis for log xanthine.

**Table S4** \| Correlation analysis for log xanthine oxidoreductase.

**Table S5** \| Correlation analysis for uric acid.
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